INSIGHTS ON UPSTREAM MANUFACTURING
-
How Can We Build Trust In Model-Driven Manufacturing?
Data is abundant, but turning it into trusted prediction is harder. Model-driven control depends on process understanding, organizational capability, and trust as much as technology.
-
Navigating One Of Biomanufacturing's Most Contentious Decisions
Single-use and stainless steel bioreactors share core engineering, so real differences lie in the operations. See how the development stage and commercial trajectory outweigh allegiance to either.
-
Amino Acids For cGMP Biopharmaceutical Manufacturing
cGMP-grade amino acids require more than chemical specifications. Documentation, supplier controls, traceability, and intended use shape suitability for regulated processes.
-
Why Reagent Quality Defines Research Success
Water grade, buffer preparation, and packaging each shape whether sensitive assays hold up. Reagent selection hinges on matching purity to application sensitivity, regulatory standards, and tolerance for contamination risk.
-
The Critical Role Of Amino Acids In Biopharmaceutical Manufacturing10/14/2026
Lot-to-lot control, documentation, and supply continuity for media amino acids become increasingly pressing questions as mammalian and microbial processes move toward commercial manufacturing.
-
Guiding Process Performance Across Sites, Scales, And Bioreactor Systems10/14/2026
The real risk in process transfer emerges when changes in scale, equipment, site, or team reveal what the plan couldn’t anticipate.
-
High-Yield Cell Therapy Bioproduction10/14/2026
Producing billions of dental pulp stem cells strains static culture and complicates harvest. A closed planar perfusion approach offers another route, with scale-up lessons from one developer.
-
Intensifying Cell Production Processes Through Real-Time Control10/14/2026
Real-time lactate readings steering ATF perfusion automatically offer a route to denser, more scalable NK cell cultures while maintaining viability, a contrast with the limits of batch and fed-batch.
UPSTREAM MANUFACTURING SOLUTIONS
-
Leverage the latest genome editing technologies and our exclusive innovations for your mammalian cell line engineering project
-
Eliminating HLA expression limits T-cell recognition but can invite NK-cell attack. A hypoimmune iPSC line pairs B2M and CIITA knockouts with five immune-modulatory knock-ins to address both arms.
-
A single fed-batch, chemically defined medium carries MSC and fibroblast cultures from seeding through harvest, extending the exosome collection window and avoiding losses at media exchanges and washes.
-
Two 4,000L fermenters, run singly or in parallel, extend microbial capacity at mid scale, aiming to carry a program from clinical supply through launch and commercial without changing sites.
-
Large-scale microbial fermentation raises hard questions about scale-up, primary recovery, and capacity. A 15,000L multi-product setup in Switzerland addresses them within a broader range of cGMP scales, from 70L upward.